GP
SVA

GLG Partners’s Sinovac Biotech, Ltd SVA Stock Holding History

GLG Partners’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$2.14M Sell
271,072
-487,787
-64% -$3.65M 0.1% 218
2017
Q3 		$5.34M Buy
758,859
+476,248
+169% +$3.25M 0.28% 110
2017
Q2 		$1.91M Buy
282,611
+167,165
+145% +$916K 0.11% 207
2017
Q1 		$661K Buy
115,446
+90,707
+367% +$525K 0.03% 313
2016
Q4 		$146K Sell
24,739
-33,061
-57% -$199K 0.01% 356
2016
Q3 		$341K Hold
57,800
– – 0.01% 398
2016
Q2 		$343K Buy
+57,800
New +$354K 0.01% 372

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GLG Partners's SVA Position: Q4 2017 in Review

GLG Partners reduced its Sinovac Biotech, Ltd (SVA) stake by 64% in Q4 2017, selling an estimated $3.65M and leaving 271,072 shares worth $2.14M. The position accounts for 0.1% of the portfolio, ranked #218.

GLG Partners first reported a position in SVA in Q2 2016 and has held it in 7 quarters since. The position peaked at $5.34M in Q3 2017. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

  • GLG Partners held 271,072 shares of Sinovac Biotech, Ltd worth $2.14M as of Q4 2017.
  • GLG Partners sold 487,787 Sinovac Biotech, Ltd shares in Q4 2017, an estimated $3.65M.
  • Sinovac Biotech, Ltd made up 0.1% of GLG Partners's portfolio in Q4 2017, its #218 holding.
  • GLG Partners first reported a position in Sinovac Biotech, Ltd in Q2 2016 and has held it in 7 quarters since.
  • GLG Partners's Sinovac Biotech, Ltd position peaked at $5.34M in Q3 2017.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.